Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofogliflozin - Chugai Pharmaceutical

Next Previous
Drug Profile

Tofogliflozin - Chugai Pharmaceutical

Alternative Names: Apleway; CSG452; Deberza; R 7201; RG 7201; RO4998452; Tofogliflozin hydrate

Latest Information Update: 06 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Kowa; Osaka University School of Medicine; Sanofi K.K.
  • Class Antihyperglycaemics; Benzhydryl compounds; Benzofurans; Cardiovascular therapies; Glucosides; Hepatoprotectants; Small molecules; Spiro compounds; Vascular disorder therapies
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Atherosclerosis

Most Recent Events

  • 03 Jun 2026 Phase-II clinical trials in Non-alcoholic steatohepatitis (Combination therapy) in Argentina, Brazil, Canada, Japan, Spain, Bulgaria (PO) (NCT05327127)
  • 03 Jun 2026 Kowa completes a phase-II clinical trials in Non-alcoholic steatohepatitis (Combination therapy) in USA, Argentina, Brazil, Canada, Japan, Spain, Bulgaria (PO) (NCT05327127)
  • 14 Apr 2022 Phase-II clinical trials in Non-alcoholic steatohepatitis (Combination therapy) in USA (PO) (NCT05327127)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top